← Back to Search

Other

Cisplatin for Pancreatic Cancer

Phase 2
Waitlist Available
Research Sponsored by CanBas Co. Ltd.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up one year
Awards & highlights

Study Summary

This trial is testing the combination of a new drug (CBP501) with cisplatin and nivolumab to treat patients with exocrine pancreatic cancer that has spread and has a low white blood cell count.

Eligible Conditions
  • Pancreatic Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~one year
This trial's timeline: 3 weeks for screening, Varies for treatment, and one year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Three-month progression free survival rate (3M PFSR)
Secondary outcome measures
Confirmed and timepoint objective response rates (cORR/ORR)
Duration of responses (DoR)
Overall survival (OS)
+3 more

Side effects data

From 2012 Phase 3 trial • 256 Patients • NCT01005680
51%
Neutropenia
47%
Leukopenia
46%
Nausea
43%
Vomiting
35%
Anaemia
31%
Decreased appetite
26%
Haemoglobin decreased
26%
Fatigue
25%
Constipation
25%
White blood cell count decreased
24%
Neutrophil count decreased
19%
Alanine aminotransferase increased
13%
Platelet count decreased
12%
Rash
10%
Aspartate aminotransferase increased
10%
Thrombocytopenia
9%
Blood sodium decreased
8%
Hypokalaemia
7%
Insomnia
7%
Pyrexia
6%
Hyponatraemia
6%
Blood creatinine increased
6%
Lymphopenia
6%
Diarrhoea
6%
Dyspepsia
6%
Red blood cell count decreased
6%
Cough
4%
Dizziness
2%
Bone marrow failure
1%
Ischaemic stroke
1%
Cerebral infarction
1%
Dyspnoea
1%
Pulmonary embolism
1%
Embolism venous
1%
Superior vena cava syndrome
100%
80%
60%
40%
20%
0%
Study treatment Arm
Gemcitabine Plus Cisplatin (GC)
Pemetrexed Plus Cisplatin (PC)

Trial Design

4Treatment groups
Experimental Treatment
Group I: Arm 4: Cisplatin + NivolumabExperimental Treatment2 Interventions
Cisplatin 60mg/m2 will be administered as infusion and then Nivolumab 240mg will be administered.
Group II: Arm 3: CBP501 (25) + CisplatinExperimental Treatment2 Interventions
CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously.
Group III: Arm 2: CBP501 (16) + Cisplatin + NivolumabExperimental Treatment3 Interventions
CBP501 16mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
Group IV: Arm 1: CBP501 (25) + Cisplatin + NivolumabExperimental Treatment3 Interventions
CBP501 25mg/m2 and Cisplatin 60mg/m2 will be administered simultaneously. Nivolumab 240mg will be administered following the completion of CBP501 and cisplatin infusions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nivolumab
2014
Completed Phase 3
~4750
CBP501 (25)
2021
Completed Phase 2
~40
CBP501 (16)
2021
Completed Phase 2
~40
Cisplatin
2013
Completed Phase 3
~1940

Find a Location

Who is running the clinical trial?

CanBas Co. Ltd.Lead Sponsor
4 Previous Clinical Trials
359 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Bioorganic & Medicinal ChemistryJournal
Screening of a Library of T7 Phage-displayed Peptides Identifies Alphac Helix in 14-3-3 Protein as a Cbp501-binding Site
Matsumoto, Yuki, Yosuke Shindo, Yoichi Takakusagi, Kaori Takakusagi, Senko Tsukuda, Tomoe Kusayanagi, Hitoshi Sato, Takumi Kawabe, Fumio Sugawara, and Kengo Sakaguchi. 2011. “Screening of a Library of T7 Phage-displayed Peptides Identifies Alphac Helix in 14-3-3 Protein as a Cbp501-binding Site”. Bioorganic & Medicinal Chemistry. Elsevier BV. doi:10.1016/j.bmc.2011.10.004.
Molecular Cancer TherapeuticsJournal
Cbp501-calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin
Mine, Naoki, Sayaka Yamamoto, Naoya Saito, Satoshi Yamazaki, Chikako Suda, Machiyo Ishigaki, Donald W. Kufe, Daniel D. Von Hoff, and Takumi Kawabe. 2011. “Cbp501-calmodulin Binding Contributes to Sensitizing Tumor Cells to Cisplatin and Bleomycin”. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.mct-10-1139.
Molecular Cancer TherapeuticsJournal
Cell Cycle Phenotype-based Optimization of G2-abrogating Peptides Yields CBP501 with a Unique Mechanism of Action at the G2 Checkpoint
Sha, Shi-Ken, Takuji Sato, Hidetaka Kobayashi, Machiyo Ishigaki, Sayaka Yamamoto, Hitoshi Sato, Asako Takada, et al.. 2007. “Cell Cycle Phenotype-based Optimization of G2-abrogating Peptides Yields CBP501 with a Unique Mechanism of Action at the G2 Checkpoint”. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.mct-06-0371.
in VitroJournal
Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 <i>in Vitro</i>
Mine, Naoki, Sayaka Yamamoto, Donald W. Kufe, Daniel D. Von Hoff, and Takumi Kawabe. 2014. “Activation of Nrf2 Pathways Correlates with Resistance of NSCLC Cell Lines to CBP501 in Vitro”. Molecular Cancer Therapeutics. American Association for Cancer Research (AACR). doi:10.1158/1535-7163.mct-13-0808.
~11 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top